Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

Identifieur interne : 001217 ( Ncbi/Checkpoint ); précédent : 001216; suivant : 001218

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.

Auteurs : Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol ; Cristina Sampaio

Source :

RBID : pubmed:15818599

English descriptors

Abstract

The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non- efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.

DOI: 10.1002/mds.20464
PubMed: 15818599


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:15818599

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.</title>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612, USA. cgoetz@rush.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612</wicri:regionArea>
<wicri:noRegion>Illinois 60612</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation>
<country>Autriche</country>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="doi">10.1002/mds.20464</idno>
<idno type="RBID">pubmed:15818599</idno>
<idno type="pmid">15818599</idno>
<idno type="wicri:Area/PubMed/Corpus">003084</idno>
<idno type="wicri:Area/PubMed/Curation">003084</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003137</idno>
<idno type="wicri:Area/Ncbi/Merge">001217</idno>
<idno type="wicri:Area/Ncbi/Curation">001217</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001217</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.</title>
<author>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612, USA. cgoetz@rush.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Department of Pharmacology, Rush University Medical Center, Chicago, Illinois 60612</wicri:regionArea>
<wicri:noRegion>Illinois 60612</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation>
<country>Autriche</country>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Amantadine (therapeutic use)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Apomorphine (therapeutic use)</term>
<term>Benzophenones (therapeutic use)</term>
<term>Benzothiazoles</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
<term>Deep Brain Stimulation (methods)</term>
<term>Dihydroergocryptine (therapeutic use)</term>
<term>Ergolines (therapeutic use)</term>
<term>Fetal Tissue Transplantation (methods)</term>
<term>Globus Pallidus (surgery)</term>
<term>Humans</term>
<term>Indans (therapeutic use)</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa (therapeutic use)</term>
<term>Lisuride (therapeutic use)</term>
<term>Mesencephalon (cytology)</term>
<term>Mesencephalon (embryology)</term>
<term>Monoamine Oxidase Inhibitors (therapeutic use)</term>
<term>Neurosurgical Procedures (methods)</term>
<term>Nitrophenols (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (surgery)</term>
<term>Pergolide (therapeutic use)</term>
<term>Piribedil (therapeutic use)</term>
<term>Selegiline (therapeutic use)</term>
<term>Thiazoles (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Amantadine</term>
<term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Benzophenones</term>
<term>Bromocriptine</term>
<term>Dihydroergocryptine</term>
<term>Ergolines</term>
<term>Indans</term>
<term>Indoles</term>
<term>Levodopa</term>
<term>Lisuride</term>
<term>Monoamine Oxidase Inhibitors</term>
<term>Nitrophenols</term>
<term>Pergolide</term>
<term>Piribedil</term>
<term>Selegiline</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Benzothiazoles</term>
<term>Catechol O-Methyltransferase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Mesencephalon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="embryology" xml:lang="en">
<term>Mesencephalon</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Deep Brain Stimulation</term>
<term>Fetal Tissue Transplantation</term>
<term>Neurosurgical Procedures</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Globus Pallidus</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The objective of this study is to update a previous evidence-based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001-January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non-Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty-seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non- efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non-efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy-based reviews is essential. We consider a 3-year period a reasonable time frame for published updates and are working to establish a Web-based mechanism to update the report in an ongoing manner.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Autriche</li>
<li>États-Unis</li>
</country>
<region>
<li>Tyrol (Land)</li>
</region>
<settlement>
<li>Innsbruck</li>
</settlement>
<orgName>
<li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</noCountry>
<country name="États-Unis">
<noRegion>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
</noRegion>
</country>
<country name="Autriche">
<region name="Tyrol (Land)">
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001217 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001217 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:15818599
   |texte=   Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i   -Sk "pubmed:15818599" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024